At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jun 22, 2026 at 07:30 ET
BridgeBio announced additional positive data from the Phase 3 PROPEL 3 study of oral infigratinib in achondroplasia will be presented at ICCBH 2026, alongside other skeletal dysplasia and ADH1 data. This is a routine pipeline update with no new regulatory or commercial catalyst, the data was previously disclosed and the presentation is a conference update, not a new approval or trial result.
- Positive data from PROPEL 3 Phase 3 study of oral infigratinib in achondroplasia to be presented in late-breaking oral at ICCBH 2026 on June 28.
- Additional presentations include quality-of-life findings from PROPEL observational study, Phase 2/2b design for children under 3, and ADH1 CLARIFY study poster.
- No new regulatory filing, approval, or commercial milestone announced, this is a conference data presentation update.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access